Guilin Huaxin Pharmacy Co. Ltd.

Main purpose: This study used benidipine hydrochloride tablets (specification: 8 mg) owned by Guilin Huaxin Pharmaceutical Co., Ltd. and produced by Guilin Huaxin Pharmaceutical Co., Ltd. as the test preparation. According to the relevant regulations of bioequivalence studies, benidipine hydrochloride tablets (specification: 8 mg, trade name: Coniel® /Coniel®) owned by Kyowa Kirin Co., Ltd. were used as the reference preparation to evaluate the bioequivalence of the test preparation and the reference preparation after administration under fasting/postprandial conditions. Secondary purpose: Observe the safety of the test preparation benidipine hydrochloride tablets and the reference preparation benidipine hydrochloride tablets (Coniel® /Coniel®) in healthy subjects.

In this study, Candesartan cilexetil tablets (specification: each tablet contains 16 mg of candesartan cilexetil and 12.5 mg of hydrochlorothiazide) developed by Guilin Huaxin Pharmaceutical Co., Ltd. were used as the test preparation. According to the relevant regulations of bioequivalence studies, Candesartan cilexetil tablets (specification: each tablet contains 16 mg of candesartan cilexetil and 12.5 mg of hydrochlorothiazide, trade name: Blopress®) owned by CHEPHAPHARM Arzneimittel GmbH and produced by Delpharm Novara S.r.l. were used as the reference preparation to evaluate the bioequivalence of the test preparation and the reference preparation after administration under fasting/postprandial conditions.

To compare the differences in absorption extent and rate between the fexofenadine hydrochloride dry suspension (30 mg) provided by Guilin Huaxin Pharmaceutical Co., Ltd. and the fexofenadine hydrochloride dry syrup (trade name: Allegra®, specification: 30 mg/0.6 g) produced by Sanofi Co., Ltd. under fasting and postprandial administration in healthy Chinese people, and to evaluate the safety of the fexofenadine hydrochloride dry suspension produced by Guilin Huaxin Pharmaceutical Co., Ltd.